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Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C 
regardless of HCV genotype. This combination therapy achieves higher response rates than previous therapy, but, 
nevertheless, a large proportion of patients suffer from treatment failure or adverse events. Recent clinical studies of viral 
kinetics during antiviral treatment have led to the introduction of response-guided therapy, the concept of ‘customized therapy 
depending on viral response’, which focuses on modulation of the treatment period depending on the viral response to create a 
sustained viral response without unnecessary medication and costs. New upcoming direct-acting antivirals (DAAs) maximize 
response rate, and triple therapy including DAAs along with pegylated interferon and ribavirin combination therapy could soon 
be the standard therapy. In this article, we reviewed the factors affecting treatment, response guided treatment, retreatment after 
failure of standard treatment, management of adverse events during treatment, and new treatment options. (Korean J Hepatol 
2012;18:22-28)
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INTRODUCTION
Chronic hepatitis C affects an estimated 1-2% of the 
Korean population and is one of the leading causes of liver 
cirrhosis and hepatocellular carcinoma in Korea.
1 Over the 
past decade, pegylated interferon (peginterferon) and ribavirin 
combination therapy has become the standard antiviral 
treatment for chronic hepatitis C regardless of hepatitis C 
virus (HCV) genotype. Although standard peginterferon and 
ribavirin combination therapy achieves better response rates 
than previous interferon and ribavirin combination therapy 
or peginterferon monotherapy, a high proportion of patients 
still suffer from treatment failure or adverse effects of the 
therapy.
The recent results of clinical trials show that there has 
been much progress in the treatment of chronic hepatitis C. 
Viral kinetics during antiviral treatment has emerged as an 
important predictor of treatment response and is used to 
guide treatment: the more rapidly HCV RNA disappears 
during treatment, the higher the response rate to treatment is. 
This suggested that the viral response to treatment could 
be used to modify treatment duration. Response- guided 
therapy, the concept of ‘customized therapy depending on 
viral response’, which modifies the treatment period 
depending on the viral response, is a newly emerging ‘proof 
of concept’. Shorter treatments would not only improve 
overall tolerability, but also reduce unnecessary medication 
and expense.
In this article, we reviewed recently updated American 
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Table 1. Sustained viral response rate of pegylated interferon and ribavirin combined treatment in Korea
Genotype 1 Genotype 2 or 3 Center Region Reference
69.6% 90.2% Single Gyeongnam 2008 KASL meeting
9
69.0% 78.9% Single Seoul 2009 KASL meeting
10
49.3% 80% Single Daegu 2009 KASL meeting
11
58.7% 86.3% Multicenter Daejeon 2008 KASL meeting
12
53.6% 71.4% Multicenter Gyeonggi-Incheon 2010 KASL meeting
13
80.8% 92.7% Single Busan 2010 KASL meeting
14
57.8% 86.8% Multicenter National wide 2010 KASL meeting
12
KASL, The Korean Association for the Study of the Liver.
European Association for the Study of the Liver (EASL) 
practice guidelines for chronic hepatitis C,
2-4 and compared 
them with Korean data. Upcoming DAAs were also 
mentioned. We focused on the factors affecting treatment, 
response guided treatment, retreatment after failure of 
standard treatment, management of adverse events during 
treatment, and new treatment options.
Factors affecting the duration and outcome of 
treatment for chronic hepatitis C
With the development of peginterferon, treatment outcomes 
have improved and combination therapy with peginterferon 
and ribavirin is currently acknowledged to be the standard 
antiviral treatment of chronic hepatitis C.
The viral genotype is one of the most important factors 
affecting the duration and outcome of antiviral treatment.
2 
Among the six genotypes of HCV, 48 week combination 
therapy is recommended as standard treatment for 
genotypes 1 and 4, whereas 24 week combination therapy is 
recommended for genotypes 2 and 3.
1 Further studies are 
needed to define the standard duration for genotype 6, the 
most common genotype in Asia. In Western countries, the 
reported sustained virological response (SVR) rate is 40-50% 
for genotype 1 and 70-80% for genotypes 2 and 3.
5 A higher 
response rate is reported in Korea: the SVR rate of genotype 
1 is around 60-70% and those of genotypes 2 and 3 reach 
80-90% (Table 1). However more prospective studies are 
needed in Korea because most of the studies have been 
retrospective and there are many differences in treatment 
outcomes by research institutes.
A low baseline HCV RNA level before treatment as well 
as the viral genotype is important factors affecting treatment 
outcome, and has considerable influence on decisions about 
duration of treatment in patients showing rapid virological 
responses. A low HCV RNA level is defined as <600,000 
IU/mL by AASLD and 400,000-800,000 IU/mL by EASL.
4
A host genetic polymorphism upstream of the IL28B gene 
on chromosome 19 has been recently identified as a strong 
indicator of a SVR to combination therapy with peginter-
feron alpha and ribavirin and spontaneous clearance of 
acute HCV infection, particularly in asymptomatic 
patients.
6,7  The IL-28B polymorphism can help explain 
individual and racial differences in responses to standard 
combination therapy. However, additional studies are needed 
because IL-28B as a predictor has some disadvantages such 
as low accuracy in predicting treatment success in individual 
patients.
Other factors affecting the outcome of treatment include 
the stage of fibrosis, body mass index, insulin resistance, 
age, gender, and co-infection with another hepatotropic virus 
or with HIV.
8
Viral kinetics in chronic hepatitis C
Undetectable HCV RNA in a sensitive assay at treatment 
week 4 is referred to as rapid virological response (RVR).
4 A 
sensitive HCV RNA assay is defined as one with a lower 
limit of detection of 50 IU/mL.
4 It is known that the 
probability of a SVR is high regardless of viral genotype 
when RVR is attained. Although early termination of antiviral 
therapy may be considered in some selected patients with 
RVR, absence of RVR does not justify extending the duration 
of treatment because of its low predictability.
15-18
An early virological response (EVR) is defined as a 2 log 
reduction of HCV RNA levels or the disappearance of 
HCV RNA at treatment week 12. A partial EVR (pEVR) is 
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RNA levels compared to baseline level, and a complete EVR 
(cEVR) is defined as undetectable HCV RNA at treatment 
week 12.
2 A virological response at treatment week 12 is 
known as a predictor of SVR in genotype 1 chronic 
hepatitis C.
19,20
The AASLD practice guidelines recommend that treatment 
should be stopped if HCV RNA is detectable at treatment 
week 24 and extended to 72 weeks if HCV RNA is negative 
at treatment week 24 in genotype 1 patients with pEVR. 
However, the EASL practice guidelines recommend that the 
HCV RNA level should be measured at treatment week 4 
and 12 regardless of genotype and treatment be stopped in 
genotypes 2 and 3 as well as 1 if there is not at least a 2 log 
decrease of HCV RNA from baseline.
4
Short term therapy in patients with rapid 
virological response
In genotype 1 chronic hepatitis C, it is reported that the 
treatment outcomes of 24 week short term therapy are 
comparable to those of 48 week standard therapy in patients 
with RVR and low pre-treatment HCV RNA levels 
(<600,000 IU/mL).
16,21-23 There have been two studies of 
short term therapy in genotype 1 patients in Korea. One 
study of 50 patients with RVR reported that the number of 
SVR with 24 week short term therapy did not differ from 
that with 48 week therapy.
24 The other retrospective study of 
343 patients reported that all patients with low HCV RNA 
levels before treatment and RVR after treatment attained 
SVR with 24 week short term therapy.
14 The recent EASL 
practice guidelines recommend 24 week therapy for patients 
who have low pre-treatment HCV RNA levels (400,000- 
800,000 IU/mL) and attain RVR.
4 Short term therapy can be 
considered selectively in genotype 1 patients with low baseline 
HCV RNA levels who achieve RVR when maintaining the 
therapy is difficult because of adverse effects (Fig. 1). 
However, additional prospective randomized control studies 
are needed in Korea.
In recent studies with genotype 2 and 3 chronic hepatitis 
C, shortening of treatment from 24 to 16 weeks resulted in 
the same treatment outcomes in terms of SVR in patients 
who attained RVR.
2,17,18 In addition, a retrospective Korean 
study of 163 chronic hepatitis C patients found no difference 
in SVR between 16 week short term therapy and 24 week 
standard therapy (96.8% vs. 95.1%) in patients with genotype 
2 or 3 who had reached RVR.
14 EASL practice guidelines 
recommend short term therapy of 12-16 weeks be 
considered in patients with RVR and low baseline viral loads 
(<400,000-800,000 IU/mL), but the evidence for the equal 
efficacy of shortened treatment is insufficient in patients 
with negative predictors of response such as advanced 
fibrosis and cirrhosis, metabolic syndrome, insulin resistance, 
and hepatic steatosis.
4 In summary, short term therapy can be 
considered selectively in genotype 2 and 3 patients if they 
have RVR, low baseline viral loads, and no negative response 
predictors (Fig. 1).
Extended therapy in patients with delayed viral 
response
A delayed viral response (DVR) is defined as undetectable 
HCV RNA at treatment week 24 in genotype 1 patients with 
pEVR. In recent studies, 72 week extended therapy yielded 
significantly more SVR than 48 week standard therapy in 
genotype 1 patients with DVR.
25,26 In Europe, 72 week 
extended therapy is recommended for genotype 1 patients 
showing DVR (Fig. 1).
4 Another study obtained the 
opposite result
27 and there are no data in Korea yet. 
Therefore, extended therapy for genotype 1 patients should 
be used with care, taking into account the patients' 
characteristics before treatment, adverse effects of treatment, 
compliance and socio-economic circumstances of the 
patients as well as virological responses to treatment.
EASL practice guidelines recommend 48 week extended 
therapy for genotype 2 and 3 patients with pEVR (Fig. 1).
4 
However, study results for extended therapy for genotypes 2 
and 3 are very limited and domestic data are insufficient. For 
genotype 4 patients, therapy as for genotype 1 is recom-
mended, but there are no recommendations for ‘response 
guide treatment’ relating to genotypes 5 and 6.
Retreatment of patients who failed standard 
therapy
A quarter of patients who receive standard therapy with 
peginterferon and ribavirin experience treatment failure and 
do not attain SVR. Treatment failure can be divided into 
non-response and relapse. Studies of retreatment with pegin-
terferon and ribavirin have reported that SVR rate was 42% 
in the relapsed patients who had treated with non-pegylated 
interferon and ribavirin,
28 and 33% in the relapsed patients 
who had treated with peginterferon and ribavirin.
29 There 
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Figure 1. Response-guided therapy in chronic hepatitis C. There is weak evidence that the algorithm for genotype 1 can also be applied 
to genotype 4, and there is also weak evidence that the algorithm for genotypes 2 and 3 can be applied to genotypes 5 and 6, excluding 
12-16  week  therapy.  The  dotted  lines  indicate  weak  evidence.  PEG, pegylated; IFN, interferon; HCV, hepatitis C virus; RVR, rapid 
virological response.
responders after 48 week standard treatment (EPIC-3, 
REPEAT). The SVR rates after retreatment was as low as 
6% in the EPIC-3 program and 9% in the REPEAT trial. 
However, the SVR rates did increase significantly but only 
to 16% when 72 week extended treatment was performed in 
the REPEAT trial.
30 Interestingly, treatment success rates 
were relatively high in both the EPIC-3 and REPEAT trials 
when EVR was obtained after retreatment. 
Two retrospective studies regarding the retreatment of 
Korean patients have been published as abstracts. The 
results in summary are as follows. Among patients who had 
used peginterferon and ribavirin, SVR rate was 0% (n=1) in 
the non- responders and 70% (n=10) in the relapsed patients. 
Among patients who had used non-pegylated interferon and 
ribavirin, SVR rate was 17.6% (n=17) in non-responders and 
81.3% (n=16) in relapsed patients.
31,32 
In conclusion, retreatment with peginterferon and ribavirin 
should be considered in patients who received non- 
pegylated interferon or peginterferon monotherapy.
2 
However, when SVR is not attained despite an adequate 
period of treatment with peginterferon and ribavirin, careful 
consideration should precede retreatment with the same 
drugs. In Europe, retreatment is not recommended for non- 
responders to standard therapy that includes peginterferon. 
In such cases, triple combination therapy including a 
protease inhibitor which is expected to be released onto the 
market soon may be considered.
Management of adverse effects during treatment
Adverse effects associated with combination therapy with 
interferon and ribavirin are relatively frequent. It has been 
reported that 10-14% of patients discontinued treatment 
because of adverse effects.
20,33 
A decrease in hemoglobin develops within the first 4 
weeks after initiation of the therapy and larger doses of 
ribavirin result in more severe decrease. Ribavirin is 
contraindicated in the patients with chronic renal failure 
because the risk of hemolytic anemia is high by the 
accumulation of ribavirin. It is currently recommended to 
reduce the ribavirin dose to 600 mg if Hb decreases to <10 
g/dL and to discontinue ribavirin if Hb is <8.5 g/dL. 
However, as SVR is higher in patients treated with high dose 
ribavirin in the initial phase and decreases dramatically 
when the dose is reduced within the first 12 weeks of 
treatment, careful consideration is needed before making a 
decision to reduce the ribavirin dose in asymptomatic 
anemic patients. Although with a lack of evidence about 
whether the use of erythropoietin (EPO) increases treatment 
success, the use of EPO in the initial phase of treatment 
(within the first 12 weeks) may decrease the frequency of 
ribavirin dose reduction, and improve the general condition 
of patients, and thus increase the drug compliance and the 
SVR. Therefore, selective use of EPO should be considered 
if hemoglobin is <10 g/dL. 
Neutropenia is defined as <1,500 neutrophils/mm
3 (ANC) 
and severe neutropenia is defined as ANC <500/mm
3 in 
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peripheral blood. Both occur in 18-20% and 4% of the 
patients during treatment respectively. It was recommended 
in a large study to halve the dose of peginterferon if ANC is 
reduced to <750/mm
3and to discontinue peginterferon if 
ANC is reduced to <500/mm
3. However, no accurate clinical 
guidance regarding neutropenia has been established.
20,33,34 
Granulocyte colony stimulating factor (G-CSF) is often used 
in severe neutropenic patients with fever after anti-cancer 
therapy, and has been shown to reduce mortality associated 
with infections. While a number of clinicians have tried 
using G-CSF in the antiviral therapy of chronic hepatitis C, 
cases other than hepatic cirrhosis patients requiring G-CSF 
are rare as severe infections are not common during the 
therapy even in cases of neutropenia.
35 In the studies that 
used 150-300 μg of G-CSF weekly, increase in ANC, not in 
SVR was demonstrated.
36,37
As for platelets, it is recommended to halve the dose 
of peginterferon if they decline to <50,000/mm
3 and to 
discontinue peginterferon if they are <30,000/mm
3. In a 
phase II clinical trial, eltrombopag, an oral thrombopoietin 
mimetic, was shown to increase platelet count in type C 
hepatic cirrhosis patients and significantly increased the 
number of patients who were able to complete 12 week 
antiviral treatment.
38 A  phase III clinical trial is required to 
evaluate its effects on SVR. 
New hepatitis C drugs
The most studied DAAs against hepatitis C virus are 
telaprevir (TVR) and boceprevir (BOC), which are NS3/4 
protease inhibitor.
Although TVR induced rapid and extensive virus in-
hibition in 14 day monotherapy in phase I clinical trial (a 4.4 
log reduction from that before treatment) and awakened 
great expectations, virological breakthrough due to the 
emergence of drug-resistant strains occurred in a number of 
patients who received it as monotherapy. Therefore trials to 
improve SVR by combining TVR with peginterferon and 
ribavirin have been undertaken. In the PROVE1 and 
PROVE2 trials, a marked increase of SVR was observed 
when this combination was used for the initial 12 weeks in 
treatment-naive genotype 1 patients (60-69% vs. 48%), and 
in the PROVE3 study, a notable increase of SVR was seen 
when the same treatment was used in treatment-experienced 
genotype 1 patients (51-53% vs. 14%).
39-41
BOC, a reversible covalent inhibitor of the NS3/4 
protease similar to telaprevir, had a strong antiviral effect in 
vitro, and was effective when combined with peginterferon. 
In patients with genotype 1 hepatitis C who had not 
responded to the initial therapies in phase I clinical trial, the 
combination of BOC with peginterferon decreased HCV 
RNA more effectively than monotherapy with BOC or 
peginterferon.
42,43 Recently, the results of the comparison of 
triple therapy (BOC plus standard therapy) with standard 
therapy in 1097 patients with genotype 1 chronic hepatitis C 
have been reported (SPLINT-2 study).
42 In that trial, SVR 
rate for the 24 week and 44 week treatment groups receiving 
the boceprevir-containing regimen were 66% and 67%, 
respectively, which were significantly higher than the 40% 
in the standard therapy. The addition of BOC to peginterferon- 
ribavirin also resulted in significantly higher SVR rate 
than that of peginterferon-ribavirin alone in previously 
treated genotype 1 chronic hepatitis C patients (66% vs. 
21%, respectively).
The use of BOC or TVR in combination with peginterferon 
alfa and ribavirin is accepted as the optimal therapy for 
genotype 1 in recently updated AASLD guideline.
3 Triple 
therapy involving the addition of a protease inhibitor or 
other DAAs to the present standard therapy could soon 
become the standard treatment. In particular, a role for 
protease inhibitors may be anticipated in the retreatment of 
patients in whom peginterferon and ribavirin combination 
therapy have failed.
CONCLUSION
The goal of antiviral treatment in chronic hepatitis C is 
eradication of HCV to prevent progression of the liver 
disease. Antiviral therapy based on peginterferon and 
ribavirin combination therapy achieves an acceptable response 
rate, and response guided therapy improves response rate 
and tolerability by reducing medication and expense. With 
the improvement of response rate and tolerability of this 
treatment chronic hepatitis C with normal liver function has 
become widely accepted as the treatment indication. The 
recently introduced DAAs have raised response rates, and 
triple therapy with a DAA added to peginterferon and 
ribavirin combination therapy is already accepted as the 
optimal therapy for genotype 1 in AASLD guideline.
3 It 
could soon become the standard therapy.Dae Won Jun, et al. Recent trends in the treatment of chronic hepatitis C  27
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